Press release
DelveInsight's, "Presbyopia Pipeline Insight, 2025" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Presbyopia pipeline landscape. It covers the Presbyopia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Presbyopia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Presbyopia Pipeline. Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Presbyopia Pipeline Report
• In October 2025, Ocuphire Pharma Inc. announced a study is to evaluate the efficacy of Nyxol + Pilocarpine to improve DCNVA in subjects with presbyopia.
• DelveInsight's Presbyopia Pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Presbyopia treatment.
• The leading Presbyopia Companies such as Viatris, Glaukos Corporation, Tenpoint Therapeutics, Vyluma and others.
• Promising Presbyopia Pipeline Therapies such as Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine and others.
Stay ahead with the most recent pipeline outlook for Presbyopia. Get insights into clinical trials, emerging therapies, and leading companies with Presbyopia @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Presbyopia Emerging Drugs Profile
• MR-141: Viatris
MR-141 is being developed by Viatris for the treatment of presbyopia. It is a 0.75% phentolamine ophthalmic solution that works by enhancing the eye's ability to focus on near objects through muscarinic receptor targeting and mild pupil constriction. This helps expand the depth of field and improves accommodation. MR-141 is being developed in collaboration with Opus Genetics and the drug is currently in Phase III stage of its clinical trial for presbyopia.
• GLK-302: Glaukos Corporation
Glaukos Corporation is developing GLK-302, a sterile ophthalmic topical cream containing pilocarpine, intended for the treatment of presbyopia. The cream is applied to the eyelid, facilitating the transdermal delivery of pilocarpine to the eye. Pilocarpine, a muscarinic acetylcholine receptor agonist, primarily targets the M3 and M1 receptors within the eye, inducing pupillary constriction and enhancing the depth of focus. This mechanism improves near vision in individuals with presbyopia while minimally affecting distance vision. The drug is currently in Phase II stage of its clinical trial for presbyopia.
The Presbyopia Pipeline Report Provides Insights into-
• The report provides detailed insights about companies that are developing therapies for the treatment of Presbyopia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Presbyopia Treatment.
• Presbyopia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Presbyopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Presbyopia market
Explore groundbreaking therapies and clinical trials in the Presbyopia Pipeline. Access DelveInsight's detailed report now! @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Presbyopia Companies
Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio and others.
Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Presbyopia Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Learn about new drugs, Presbyopia Pipeline developments, and key companies with DelveInsight's expert analysis @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Presbyopia Pipeline Report
• Coverage- Global
• Presbyopia Companies- Viatris, Glaukos Corporation, Tenpoint Therapeutics, Vyluma and others.
• Presbyopia Pipeline Therapies- Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine and others.
• Presbyopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Presbyopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight's in-depth pipeline report today! @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents
1. Introduction
2. Executive Summary
3. Presbyopia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Presbyopia - DelveInsight's Analytical Perspective
7. Late Stage Products (Registration)
8. MR-141: Viatris
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. GLK-302: Glaukos Corporation
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Preclinical Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report.....
18. Inactive Products
19. Presbyopia - Collaborations Assessment- Licensing / Partnering / Funding
20. Presbyopia - Unmet Needs
21. Presbyopia - Market Drivers and Barriers
22. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: [email protected]
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Delete press release Edit press release News-ID: 4378827 • Views: 6
